Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment ...
Kinase inhibitorsare drugs that generally inhibittyrosine kinase(TK) enzymes, which catalyze the transfer of phosphate groups from adenosine triphosphate (ATP) totyrosine residueson proteins.14This process can be an activating event for proteins involved in signaling, and leads to increasedcellular prolif...
2015 Published: 08 December 2015 Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP- Glucuronosyltransferases Nan Zhang3, Yong Liu4 & Hyunyoung Jeong1,2 Tyrosine kinase inhibitors (TKIs) are anticancer drugs that may be co-administered with other drugs. ...
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinase signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of...
The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5
tyrosine kinase inhibitor Thesaurus Medical Acronyms Wikipedia n. Any of a class of drugs, such as imatinib, that target and block the action of specific tyrosine kinases and are used especially in the treatment of chronic myelogenous leukemia and other cancers. ...
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then bl
Protein kinase inhibitors: the tyrosine specific protein kinases. Pharmacol Ther 1998; 77(2): 81–114 PubMed CAS Google Scholar Shawver L. Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. In: Perry MC, editor. American Society of Clinical Oncology ...
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as ...
The drug–drug interaction (DDI) potential of tyrosine kinase inhibitors (TKI) as interacting drugs via transporter inhibition has not been fully assessed... T Minematsu,KM Giacomini - 《Molecular Cancer Therapeutics》 被引量: 351发表: 2011年 Efficacy of epidermal growth factor receptor tyrosine ki...